Pricing Log in Create free account

Cardiff Oncology, Inc. (CRDF) vs Xilio Therapeutics, Inc. (XLO)

Cardiff Oncology, Inc. and Xilio Therapeutics, Inc. are both Biotechnology companies. Cardiff Oncology, Inc. and Xilio Therapeutics, Inc. are of similar size ($58.8M and $55.9M). Xilio Therapeutics, Inc. grew revenue faster over the last twelve months: 327.3% against −6.79%. Xilio Therapeutics, Inc. has the higher net margin (−34.1% vs −7,889.0%) and the higher return on invested capital (0.00% vs 0.00%). Across the 14 metrics below, Xilio Therapeutics, Inc. leads on 12 and Cardiff Oncology, Inc. on 2.

Valuation

Metric CRDF XLO Biotechnology median
P/E n/m n/m 10.60
P/S 105.02 2.61 9.40
P/B 2.01 2.32 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales 39.84 0.51 9.02
Earnings yield (76.92%) (17.27%) (32.88%)
Free cash flow yield (76.74%) (36.59%) (23.13%)

Profitability

Metric CRDF XLO Biotechnology median
Gross margin 100.00% 100.00% 68.51%
Operating margin (8,320.08%) (48.94%) 0.00%
Net margin (7,888.98%) (34.06%) 0.00%
Free cash flow margin (8,059.45%) (95.59%) 0.00%
Return on equity (94.14%) (55.03%) (51.96%)
Return on assets (70.89%) (15.16%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric CRDF XLO Biotechnology median
Revenue growth (TTM) (6.79%) 327.25% 6.76%
EPS growth (last fiscal year) 27.37% 72.55% 29.88%
Revenue growth, 5-year CAGR 10.13% — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CRDF XLO Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 3.30 4.25 4.97
Net debt to EBITDA 1.18 3.40 1.01

Dividend

Metric CRDF XLO Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric CRDF XLO Biotechnology median
Market cap 58.76m 55.93m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack